Sign Up Today and Learn More About Generate Biomedicines Stock
Invest in or calculate the value of your shares in Generate Biomedicines or other pre-IPO companies through EquityZen, part of Morgan Stanley.
Generate Biomedicines Stock (GEBO)
Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.
About Generate Biomedicines Stock
Founded
2018
Headquarters
Somerville, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Generate Biomedicines Press Mentions
Stay in the know about the latest news on Generate Biomedicines
Generate Biomedicines: Post Mega-Money IPO, Caution Is Warranted
seekingalpha • Jul 25, 2026
Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?
fool • Jul 12, 2026
Generate Biomedicines falls -9.5%
thefly • Jul 10, 2026
30 U.S. Startups That IPOed in H1 2026
startupresearcher • Jul 07, 2026
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market
fool • Jun 27, 2026
Generate Biomedicines Management
Leadership team at Generate Biomedicines
Chief Scientific Officer
Michael Nohaile
Co-Founder
Sophie de Boer
Join now and verify your accreditation status to gain access to:
- Generate Biomedicines Current Valuation
- Generate Biomedicines Stock Price
- Generate Biomedicines Management
- Available deals in Generate Biomedicines and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Generate Biomedicines Cap Table and Funding History by Share Class and Liquidity Preferences
- Generate Biomedicines Revenue and Financials
- Generate Biomedicines Highlights
- Generate Biomedicines Business Model
- Generate Biomedicines Risk Factors
- Generate Biomedicines Research Report from SACRA Research
Trading Generate Biomedicines Stock
How to invest in Generate Biomedicines stock?
Accredited investors can buy pre-IPO stock in companies like Generate Biomedicines through EquityZen funds. These investments are made available by existing Generate Biomedicines shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Generate Biomedicines stock?
Shareholders can sell their Generate Biomedicines stock through EquityZen's private company marketplace. EquityZen's network includes over 470K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 55K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
